No announcement yet.

Does Young Blood Benefit MSers?

  • Filter
  • Time
  • Show
Clear All
new posts

    Does Young Blood Benefit MSers?

    This is a press release from the company, but I thought it was interesting. Blood from volunteer donors between 18-25 years old was collected and the plasma injected into MS patients.

    The Neurology Center, in an unprecedented, randomized double-blind, placebo-controlled study, designed to evaluate the efficacy of 25 ml/kg intravenous NuPlasma® young Fresh Frozen Plasma (yFFP®) administered in two doses over three days, realized dramatic improvements in critical disease-conditions such as fatigue, mobility, concentration, and urinary control. These positive initial results reflects the Parkinson's disease (PD) patient results, in which PD patients infused with NuPlasma experienced significant improvements in pain, facial expression, speech, handwriting, tremors, rigidity and falling.

    The Food and Drug Administration is discouraging people from being infused with young blood, a procedure that's becoming increasingly common but hasn't been proven to have medical benefits.

    The procedure works like it sounds. People are infused with blood plasma donated from young people. Some clinics claim the procedure works like a fountain of youth to reverse aging and memory loss or even treat diseases like dementia, Parkinson's disease, multiple sclerosis, Alzheimer's, heart disease or post-traumatic stress disorder.

    Companies typically charge thousands of dollars for the treatments. That concerns the FDA, which says these infusions are "unproven and not guided by evidence from adequate and well-controlled trials."


      Thank you, Marco!

      It has been observed for years there are benefits from doing this with blood, however, the benefits were always seen as temporary.

      What makes this different, of course, is only using "young blood". It is possible that researchers have achieved something with far more lasting benefits which may mark a very important discovery.

      Thanks again for posting such an interesting article!


        Here is a 2017 article from the MIT Technology Review, about the therapy, company, and testing process.

        As of the writing of the above article and the more recent FDA warning, Ambrosia, the startup that was providing these infusions for $8,000, has stopped doing them.

        One could say the medical establishment doesn’t want this kind of thing to put them out of business, but this kind of thing may also very easily prey on the vulnerable elderly and chronically ill.
        All the best, ~G